Ex-Vividion chief Diego Miralles finds 'dream team' at stealthy Flagship portfolio company; Astellas looks inward to select CBO and CSO
Almost three months after leaving Vividion Therapeutics, where he recently signed a $135 million Roche deal, Diego Miralles has landed the top spot on a “dream team.”
On Thursday, Flagship Pioneering officially tapped Miralles as its newest CEO-partner, where he’ll head the stealthy portfolio company Laronde. While Miralles couldn’t say much about Laronde just yet, Flagship has said it’s an early-stage biotech working on nucleic acid medicines using a “multi-modality eRNA platform.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.